Abstract
The Veterans’ Health Administration requires Prior Authorization Drug Review (PADR) evaluations for restricted formulary medications based on established criteria for use. The purpose of this study was to be able to characterize a clinical course using a combination of PADR notes and a developed ontology for treating chronic hyperkalemia, and non-treatment-related factors resulting in a physician’s request for the restricted-formulary agent patiromer, a newer agent for the treatment of chronic hyperkalemia.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
